Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
SGX Pharmaceuticals, Inc. |
---|---|
Information provided by: | SGX Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00606879 |
SGX523 is a drug which acts by blocking the function of an enzyme called MET. MET activity may be important in growth and survival of some types of cancer. This Phase I trial is studying the safety, side effects, and best dose of SGX523 when given to patients with advanced cancer, and how well it inhibits MET activity in tumors.
Condition | Intervention | Phase |
---|---|---|
Advanced Cancer |
Drug: SGX523 Capsules |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment |
Official Title: | A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, PK and PkD Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, on a Twice Daily, Uninterrupted Schedule in Patients With Advanced Cancer |
Estimated Enrollment: | 46 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Single arm: Experimental |
Drug: SGX523 Capsules
This is a dose escalation study
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Premier Onocology, California | |
Santa Monica, California, United States, 90404 | |
United States, Tennessee | |
Sarah Cannon Research Institute | |
Nashville, Tennessee, United States, 37203 |
Principal Investigator: | Lee Rosen, MD | Premier Onocology, California |
Principal Investigator: | Howard Burris, MD | Sarch Cannon Research Institute |
Responsible Party: | SGX Pharmaceuticals, Inc. ( Terry Rugg, MD ) |
Study ID Numbers: | SGX523-1A-002 |
Study First Received: | January 18, 2008 |
Last Updated: | July 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00606879 |
Health Authority: | United States: Food and Drug Administration; United States: Institutional Review Board |
Solid tumor Advanced Cancer MET inhibitor Receptor Tyrosine Kinase Inhibitor (RTKI) |
Neoplasms |